GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (XSWX:GALD) » Definitions » Cash Flow from Operations

Galderma Group AG (XSWX:GALD) Cash Flow from Operations : CHF435 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Dec. 2024, Galderma Group AG's Net Income From Continuing Operations was CHF164 Mil. Its Depreciation, Depletion and Amortization was CHF135 Mil. Its Change In Working Capital was CHF29 Mil. Its cash flow from deferred tax was CHF44 Mil. Its Cash from Discontinued Operating Activities was CHF0 Mil. Its Asset Impairment Charge was CHF0 Mil. Its Stock Based Compensation was CHF20 Mil. And its Cash Flow from Others was CHF-34 Mil. In all, Galderma Group AG's Cash Flow from Operations for the six months ended in Dec. 2024 was CHF357 Mil.


Galderma Group AG Cash Flow from Operations Historical Data

The historical data trend for Galderma Group AG's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Cash Flow from Operations Chart

Galderma Group AG Annual Data
Trend Dec23 Dec24
Cash Flow from Operations
142.69 435.10

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24
Cash Flow from Operations -149.47 286.25 78.65 356.64

Galderma Group AG Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Galderma Group AG's Cash Flow from Operations for the fiscal year that ended in Dec. 2024 is calculated as:

Galderma Group AG's Cash Flow from Operations for the quarter that ended in Dec. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF435 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galderma Group AG  (XSWX:GALD) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Galderma Group AG's net income from continuing operations for the six months ended in Dec. 2024 was CHF164 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Galderma Group AG's depreciation, depletion and amortization for the six months ended in Dec. 2024 was CHF135 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Galderma Group AG's change in working capital for the six months ended in Dec. 2024 was CHF29 Mil. It means Galderma Group AG's working capital increased by CHF29 Mil from Jun. 2024 to Dec. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Galderma Group AG's cash flow from deferred tax for the six months ended in Dec. 2024 was CHF44 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Galderma Group AG's cash from discontinued operating Activities for the six months ended in Dec. 2024 was CHF0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Galderma Group AG's asset impairment charge for the six months ended in Dec. 2024 was CHF0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Galderma Group AG's stock based compensation for the six months ended in Dec. 2024 was CHF20 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Galderma Group AG's cash flow from others for the six months ended in Dec. 2024 was CHF-34 Mil.


Galderma Group AG Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Galderma Group AG Business Description

Traded in Other Exchanges
Address
Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines